TCIM
PETX

TIAA CREF Investment Management’s Aratana Therapeutics, Inc. PETX Stock Holding History

TIAA CREF Investment Management’s Portfolio PETX Stock Details PETX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		$904K Sell
251,088
-11,257
-4% -$48.8K ﹤0.01% 2370
2018
Q4 		$1.61M Sell
262,345
-28,896
-10% -$176K ﹤0.01% 2072
2018
Q3 		$1.7M Sell
291,241
-23,441
-7% -$117K ﹤0.01% 2207
2018
Q2 		$1.34M Buy
314,682
+168,722
+116% +$851K ﹤0.01% 2377
2018
Q1 		$644K Buy
145,960
+41,540
+40% +$185K ﹤0.01% 2639
2017
Q4 		$549K Sell
104,420
-32,444
-24% -$198K ﹤0.01% 2727
2017
Q3 		$839K Sell
136,864
-89,600
-40% -$567K ﹤0.01% 2605
2017
Q2 		$1.64M Sell
226,464
-10,583
-4% -$65.1K ﹤0.01% 2303
2017
Q1 		$1.26M Sell
237,047
-38,069
-14% -$257K ﹤0.01% 2402
2016
Q4 		$1.98M Sell
275,116
-65,853
-19% -$532K ﹤0.01% 2202
2016
Q3 		$3.19K Buy
340,969
+14,829
+5% +$123K ﹤0.01% 1890
2016
Q2 		$2.06M Buy
326,140
+186,591
+134% +$1.2M ﹤0.01% 2098
2016
Q1 		$770K Buy
139,549
+40,360
+41% +$152K ﹤0.01% 2612
2015
Q4 		$553K Sell
99,189
-52,153
-34% -$345K ﹤0.01% 2859
2015
Q3 		$1.28M Sell
151,342
-9,430
-6% -$160K ﹤0.01% 2420
2015
Q2 		$2.43M Buy
160,772
+943
+0.6% +$13.6K ﹤0.01% 2178
2015
Q1 		$2.56M Buy
159,829
+10,716
+7% +$191K ﹤0.01% 2071
2014
Q4 		$2.66M Buy
149,113
+35,608
+31% +$444K ﹤0.01% 2060
2014
Q3 		$1.14M Buy
113,505
+14,783
+15% +$179K ﹤0.01% 2559
2014
Q2 		$1.54M Buy
98,722
+76,262
+340% +$1.08M ﹤0.01% 2453
2014
Q1 		$417K Buy
22,460
+5,768
+35% +$116K ﹤0.01% 2988
2013
Q4 		$319K Buy
16,692
+1,590
+11% +$32.3K ﹤0.01% 3049
2013
Q3 		$247K Buy
+15,102
New +$159K ﹤0.01% 3039

Other funds holding PETX

BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EC
Engaged Capital Newport Beach, California $303M AUM 2.09% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
JG
Jefferies Group New York $12B AUM 6.2% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
GAI
General American Investors New York $1.52B AUM 37.94% 1-Year Est. Return
GPGA
Grandeur Peak Global Advisors Salt Lake City, Utah $427M AUM 39.14% 1-Year Est. Return
Impax Asset Management Group
Impax Asset Management Group London, United Kingdom $14.3B AUM 19.8% 1-Year Est. Return

TIAA CREF Investment Management's PETX Position: Q1 2019 in Review

TIAA CREF Investment Management reduced its Aratana Therapeutics, Inc. (PETX) stake by 4.3% in Q1 2019, selling an estimated $48.8K and leaving 251,088 shares worth $904K. The position accounts for ﹤0.01% of the portfolio, ranked #2370.

TIAA CREF Investment Management first reported a position in PETX in Q3 2013 and has held it in 23 quarters since. The position peaked at $2.66M in Q4 2014. 104 funds tracked by Wall St. Rank hold PETX as of Q1 2019.

  • TIAA CREF Investment Management held 251,088 shares of Aratana Therapeutics, Inc. worth $904K as of Q1 2019.
  • TIAA CREF Investment Management sold 11,257 Aratana Therapeutics, Inc. shares in Q1 2019, an estimated $48.8K.
  • Aratana Therapeutics, Inc. made up ﹤0.01% of TIAA CREF Investment Management's portfolio in Q1 2019, its #2370 holding.
  • TIAA CREF Investment Management first reported a position in Aratana Therapeutics, Inc. in Q3 2013 and has held it in 23 quarters since.
  • TIAA CREF Investment Management's Aratana Therapeutics, Inc. position peaked at $2.66M in Q4 2014.
  • 104 funds tracked by Wall St. Rank held Aratana Therapeutics, Inc. as of Q1 2019.

Based on TIAA CREF Investment Management's 13F filing for Q1 2019, filed 14 May 2019.